Jones 1995.

Methods	DESIGN: Randomised Controlled Trial. Stratified by centre in blocks of six. METHOD OF RANDOMISATION: the word "random" stated ; method not described. METHOD OF ALLOCATION CONCEALMENT: not described. OUTCOME ASSESSOR BLINDING: not clear ‐ "data rendered anonymous" before analysis. WITHDRAWAL/DROPOUTS: not described.
Participants	Eligible: not stated Randomised: 127 Completed: 72 (Intervention self management 33; planned visits 39) Age: self managed : mean 30.4 yrs SD 11.5 yrs planned visits: mean 28.6 SD 7 yrs. Sex: Male / Female Self managed 14/19 planned visits 12/26. Asthma Diagnosis: Doctor's diagnosis Recruitment: General practices Diseases Included: Not specified Major exclusions: Those on regular oral steroids and those who were regularly conducting home PEF monitoring. Baseline: FEV1: % predicted: self management 85.1 (SD 20.8), planned visits 80.2 (SD19.9) PEF: % predicted: self management 88.2 (SD 15.4), planned visits 86.8 (SD 13.7) Exacerbations
Interventions	Setting: General Practice Type: Optimal self management: education, peak flow self monitoring, regular review and an individualised written action plan based on peak flow enabling self adjustment of medications in the event of worsening asthma. Control: regular review and kept a daily diary for morbidity and bronchodilator use for outcomes. Duration: 5 study visits (duration not stated) over a 26 week period
Outcomes	Lung Function ‐ % predicted, Use of rescue medication, quality of life, days off work, wheeze (frequency, severity), nocturnal asthma, oral corticosteroid use, cough, shortness of breath, disrupted days.
Notes	Jadad Score = 4 Oral corticosteroids was given for 2 weeks to optimise lung function in both groups during baseline. Drop outs were more likely to be younger and male with lower initial FVC values then the completers.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	Information not available